Keyphrases
Tyrosine Kinase Inhibitor Resistance
100%
Kinase Domain mutations
100%
BCP-ALL
100%
BCR-ABL1
100%
Imatinib Sensitivity
33%
PAX5
33%
Imatinib Resistance
33%
ABL1 Kinase
33%
Cell-derived
33%
IKZF1
33%
Pediatric
33%
Working Diagnosis
33%
SH2B3
16%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
16%
Chemotherapy Treatment
16%
SETD2
16%
Poor Prognostic
16%
Newly Diagnosed Patients
16%
Complete Remission
16%
Potential Biomarkers
16%
Prognostic Value
16%
Mutation-based
16%
IKZF1plus
16%
Improved Outcomes
16%
ABL1
16%
Intrinsic Mechanism
16%
ZEB2
16%
Tyrosine Kinase Inhibitor
16%
Relapsed Disease
16%
Tyrosine Kinase Inhibitor Treatment
16%
Adult Patients
16%
CRLF2
16%
Newly Diagnosed
16%
Medicine and Dentistry
Precursor
100%
Acute Lymphoblastic Leukemia
100%
B Cell
100%
Phosphotransferase
100%
Tyrosine-Kinase Inhibitor
100%
Ex Vivo
57%
Imatinib Resistance
28%
Imatinib
28%
Pediatrics
28%
Biological Marker
14%
Disease
14%
Somatics
14%
Chemotherapy
14%
Biochemistry, Genetics and Molecular Biology
Kinase
100%
Phosphotransferase
100%
Tyrosine Kinase Inhibitor
100%
Precursor
100%
B Cell
100%
Imatinib
57%
PAX5
28%
IKZF1
28%
SH2B3
14%
SETD2
14%
ZEB2
14%
CRLF2
14%
